Skip to content

LUMIERE on the FETUS

LUMIERE on the FETUS : A Study on the Added Value of Fetal MRI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04142606
Acronym
FETUS
Enrollment
1500
Registered
2019-10-29
Start date
2019-12-06
Completion date
2027-06-30
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Brief summary

Congenital anomalies are a major public health problem. They affect 2-3% of births, around 20,000 new cases per year in France, of which 15% are cared for in Ile de France. These congenital anomalies are a major cause of morbidity, infant mortality and disability. They are also a major cause of death during the infant period (22% of deaths during the first year of life: source CépiDC Inserm 2010). The detection, accurate diagnosis and accurate prognosis, particularly functional, of these congenital anomalies are still difficult in the current monitoring of pregnancy, which is based primarily on ultrasound. The use and development of modern imaging techniques is now essential to enable doctors to better see and better examine the fetus. Alongside ultrasound, Magnetic Resonance Imaging (MRI) is a technique that has undergone significant development in recent years. MRI must allow the effective anatomical and functional evaluation of the main fetal organs and could in particular be interesting in several situations in which it has not yet been sufficiently evaluated and is not yet performed in clinical routine.

Detailed description

The inclusion will take place from 16WF to 36WG, within the framework of one of the 4 clinical subgroups of patients envisaged. The standardized anatomic and functional MRI examination will in all cases last less than 45 minutes and will be based on sequences already used in clinical practice. Clinical, biological, and ultrasound data will be collected prospectively and used for the usual management of the patient. For the purposes of the study, these data will be secondarily anonymized and analyzed in connection with the MRI data and the perinatal outcome to meet the specific objectives. The lost-to-follow-up bias will be limited by the simplicity of the proposed perinatal surveillance, which does not differ from the surveillance usually recommended for these pregnancies

Interventions

The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)

Sponsors

LUMIERE Fondation ( fondation-lumiere.org) under the aegis of Fondation de France
CollaboratorUNKNOWN
University of Paris 5 - Rene Descartes
CollaboratorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient ≥ 18 years * Single or twin pregnancy * gestational age≥ 16 WG and ≤ 36 WG based on cranio-caudal length (LCC) dating * Collection of the patient's consent

Exclusion criteria

contraindication to MRI * multiple pregnancies \> 2 * subsequent follow-up impossible * maternal condition contraindicates continuation of pregnancy * patient having to have an MRI examination as part of the normal clinical follow-up of her pregnancy (identified or strongly suspected echocardiographic abnormality on ultrasound, diaphragmatic dome hernia, CMV fetal infection, antecedent brain abnormality in siblings, STT operated)

Design outcomes

Primary

MeasureTime frameDescription
feasibility of advanced MRI techniquesFrom inclusion to end of neonatal period (max 25 weeks)% of satisfactory sequences

Secondary

MeasureTime frameDescription
Concordance of information collected by MRIFrom inclusion to end of neonatal period (max 25 weeks)Concordance of the diagnosis carried out on each standardized section in ultrasound, MRI and the final diagnosis: Standardized cuts with main non-evaluable anatomical landmarks.
Acceptability of the examination for the patient: leackertLikert scaleThrough MRI study completion an average of 6 monthswill be assessed by a Likert scale. which is a psychometric tool for measuring an attitude in individuals. It consists of one or more statements (statements or items) for which the respondent expresses her degree of agreement or disagreement (5 items from 1 to 5 points : from very poor, poor, average, good, very good). A scale of several items can be summarized by the average of the item scores.
Reproducibility of the examination analysisAfter study completion, an average of one yearwill be assessed by means of Kappa coefficient
relevance of MRIFrom inclusion to end of neonatal period (max 25 weeks)will be assessed by the % of added informations
concordance of information collected by MRIFrom inclusion to end of neonatal period (max 25 weeks)Concordance of the diagnosis carried out on each standardized section in ultrasound, MRI and the final diagnosis: Standardized cuts with main anatomical landmarks seen and of usual appearance.
feasibility of fusion imaging (echo / MRI)After study completion, an average of one yearwill be assessed by the success rate of appropriate matching - % of successful echo-IRM fusion
norms of growth of main organs and placentaAfter study completion, an average of one yearCreating of normal curves by MRI measurements for length at various gestational ages
Establishment of an anatomical and functional database on a large group of healthy fetusesAfter study completion, an average of one yearBuild up of normal atlas of MRI images in normal fetuses. We will stored anonymous images of fetal brain acquired thought gestation and anatomical and using functionnal sequences
Concordance of diagnosisTermination of pregnancy (max 25 weeks)Concordance of diagnosis between virtual autopsy and foetopathology
Specific Absorption Rate for each type of sequenceAfter study completion, an average of one yearSAR is an MRI machine parameter

Countries

France

Contacts

Primary ContactDavid Grevent, MD PHD
david.grevent@gmail.com+ 33144841734
Backup ContactAminata TRAORE
aminata.traore6@aphp.fr+ 331 48 19 27 34

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026